Biotech Values

[semi_infinite]

MYOV - Sumitovant/CitiGroup purchase plan. IMO the prior CEO presented a potential impediment to purchasing cheap shares prior to final take out. Cash at $7/shr is already bloated. Sumv majority stake was purchased at $12+ a year ago.

>>>
On May 14, 2021, Sumitovant entered into the 2021 10b5-1 Trading Plan with CGMI, pursuant to which, commencing August 16, 2021,
CGMI is authorized to and directed to purchase, on behalf of Sumitovant, Common Shares on the open market up to an aggregate amount not to exceed
1,400,000 shares (exclusive of commissions of $0.02 per share purchased), subject to the satisfaction of certain conditions, including, among others,
trading price. CGMI will cease purchasing Common Shares under the 2021 10b5-1 Trading Plan on November 16, 2021. A copy of the 2021 10b5-1
Trading Plan is filed as Exhibit 99.7 hereto and the foregoing description of the 2021 10b5-1 Trading Plan is qualified in its entirety by reference to the
2021 10b5-1 Trading Plan.<<<